Browse the evidence

Semaglutide use is associated with a substantial decrease in long-term relative body weight of -12.1% compared to placebo.

Semaglutide can be considered an effective treatment option for weight loss in patients with obesity who do not have diabetes.

33.4% of participants randomized to semaglutide achieved ≥20% weight loss compared to 2.2% with placebo.

A significant proportion of patients may achieve substantial weight loss with semaglutide, making it a viable option for obesity management.

In Chinese adults with overweight or obesity, once-weekly mazdutide at a dose of 4 mg for 32 weeks led to a mean percentage change in body weight from baseline of -10.09%.

Mazdutide may be an effective treatment option for weight loss in adults with obesity or overweight.

In the 6-mg mazdutide group, the mean percentage change in body weight from baseline at week 32 was -12.55%.

Higher doses of mazdutide may lead to greater weight loss in adults with obesity or overweight.

73.9% of participants in the 4-mg mazdutide group achieved a weight reduction of at least 5% at week 32.

A significant proportion of adults with obesity or overweight may benefit from mazdutide treatment.

Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42-16.34).

Tirzepatide 15 mg is highly effective for significant weight loss in overweight and obese patients.

Tirzepatide ranked in the top three across weight-related parameters, glycemic profile, lipid parameters, and blood pressure.

Tirzepatide may provide comprehensive metabolic benefits beyond weight loss.

Tirzepatide (TZP) resulted in a mean body weight loss of 16.7 kg compared to 8.3 kg with placebo (PBO) after 18 weeks (p<0.001).

Tirzepatide may be an effective treatment for weight loss in individuals with obesity.

TZP significantly decreased food intake during lunch and dinner compared to PBO.

TZP may help reduce overall food consumption in individuals with obesity.

TZP significantly lowered appetite and food cravings compared to PBO.

TZP may be beneficial in managing appetite and cravings in individuals with obesity.

Weight management treatments (WMT) increased the probability of achieving 5% or greater weight loss.

Implementing WMT can significantly enhance weight loss outcomes for patients.

The combination of cagrilintide and semaglutide (cagrANDsema) reduced weight by -14.13 kg compared to placebo.

CagrANDsema is an effective treatment option for weight loss in individuals with obesity.

CagrANDsema also reduced glycosylated hemoglobin (HbA1c) by -0.33% compared to placebo.

CagrANDsema may help improve glycemic control in obese individuals.

Increasing physical activity is associated with the lowest obesity odds compared to stable physical activity-diet.

Practitioners should encourage increased physical activity to reduce obesity risk.

Increasing physical activity with improved diet is associated with the largest reductions in body fat percentage, body mass index, and waist circumference.

Encouraging both increased physical activity and dietary improvements can maximize fat loss.

Improvements in physical activity or diet mutually attenuated the negative effects of the deterioration of the other behavior.

Practitioners should promote improvements in either physical activity or diet to counteract declines in the other.

Time-restricted feeding (TRF) combined with a low-calorie diet resulted in significantly greater reductions in weight, BMI, waist circumference, and body fat mass compared to a low-calorie diet alone after 8 weeks.

Practitioners may consider recommending TRF combined with a low-calorie diet for better weight management in overweight and obese women with food addiction.

Nutrient-Stimulated Hormone (NuSH) therapies, specifically GLP-1 and dual/triple agonists, significantly improve clinical outcomes and functional capacity in heart failure with preserved ejection fraction (HFpEF) by reducing cardiometabolic burden and systemic inflammation, independent of weight loss alone.

If you have heart failure with preserved ejection fraction (HFpEF) and obesity, current guidelines increasingly support using GLP-1 based therapies (like semaglutide) as a core treatment, not just for weight loss but to protect your heart and kidneys. These drugs work by resetting your metabolism and reducing inflammation, offering benefits that go beyond just shedding pounds. While lifestyle changes are still important, they are often not enough on their own to overcome the body's resistance to weight loss in this specific condition. Consult your cardiologist about whether NuSH therapy is appropriate for your specific phenotype, especially if you have co-existing conditions like sleep apnea or kidney disease.

94.2% of patients achieved ≥ 5% weight loss after 6 months of tirzepatide treatment.

Practitioners can expect a high rate of significant weight loss among patients using tirzepatide.

The SASI group had greater reductions in A1C, uric acid, low-density lipoprotein, total cholesterol, and triglyceride levels compared to the SG group.

SASI may offer additional metabolic benefits for patients with obesity.

Participants assigned to a HLC diet experienced a significant 10.6 cm² greater decrease in mean VAT compared to those assigned to a HLF diet from baseline to 6 months.

Practitioners may consider recommending a HLC diet for greater VAT loss in overweight and obese individuals.

Among men, the HLC diet was associated with a 12.1 cm² greater loss of VAT compared to HLF at 12 months.

Men may benefit more from a HLC diet in terms of VAT reduction compared to a HLF diet.

The 5:2 total diet replacement (5:2TDR) resulted in a weight loss of -0.9 kg after 26 weeks, while the once-daily meal-replacement (DMR) group experienced a weight regain of 3.5 kg, leading to a between-group difference of -4.4 kg.

Practitioners may consider recommending 5:2TDR for better weight maintenance outcomes compared to DMR.

Both dietary interventions (5:2TDR and DMR) maintained weight losses greater than 15 kg below baseline at 26, 52, and 78 weeks.

Both interventions can be effective for long-term weight maintenance.